![](https://cdn.sanity.io/images/0vv8moc6/onclive/63246e5e40a26c9dd2aacef20549b9d9a8c7aae4-262x145.jpg?fit=crop&auto=format)
Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC
Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University, discusses findings from an exploratory biomarker analysis of the phase 3 KEYNOTE-426 study (NCT02853331) evaluating …